Development and evaluation of topotecan loaded solid lipid nanoparticles: A study in cervical cancer cell lines.
The study aims at statistical development of solid lipid nanoparticles (SLNs) loaded with topotecan hydrochloride for avoiding the drawbacks of conventional drug therapies used in cervical cancer. Twenty SLN batches were prepared using organic solvent evaporation method to provide response surface curves. Thereafter, optimized SLNs were obtained using numeric method based on desirability functions providing maximum drug loading and appropriate particle size. Physical characterization of optimized TPH loaded SLNs was performed in terms of particle size, zeta potential, transmission and scanning electron microscopic evaluation. Cytotoxicity studies were performed against cervical cancer cell lines, including cervical squamous cell carcinoma cell line (HeLa) and human squamous cell carcinoma cell line (SiHa). Also, Swiss mouse embryo fibroblast cells (3T3-L1) and African green monkey kidney epithelial (Vero) cells were used to evaluate biocompatibility in normal cells. As pronounced from the results, optimized SLNs may provide an attractive alternative to conventional cervical cancer drug products.
Department of Gynaecology, Linyi People's Hospital, Linyi, Shandong 276003, China. Electronic address: chenzj51@126.com.
Zhao-Jie
ZJ
Chen
Department of Gynaecology, Linyi People's Hospital, Linyi, Shandong 276003, China. Electronic address: zhzhzhang418@gmail.com.
Zhen
Z
Zhang
Department of Gynaecology, Linyi People's Hospital, Linyi, Shandong 276003, China. Electronic address: doublebxie@yeah.net.
Bei-Bei
BB
Xie
Department of Gynaecology, Linyi People's Hospital, Linyi, Shandong 276003, China. Electronic address: hyzh9998@tom.com.
Hai-Yan
HY
Zhang
D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D008055:Lipids / Q000008:administration & dosage*; D008855:Microscopy, Electron, Scanning; D053758:Nanoparticles; D059004:Topoisomerase I Inhibitors / Q000008:administration & dosage*; D019772:Topotecan / Q000008:administration & dosage*; D002583:Uterine Cervical Neoplasms / Q000473:pathology*
D008055:Lipids; D059004:Topoisomerase I Inhibitors; D019772:Topotecan
Cervical cancer; Chemotherapy; Solid lipid nanoparticles; Topotecan